VXRT logoVXRT
Vaxart Inc

75,075
Loading...
Loading...
News
all
press releases
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -13.68% and -5.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
The Beauty Health Company (SKIN) Surpasses Q2 Earnings and Revenue Estimates
Beauty Health (SKIN) delivered earnings and revenue surprises of +150.00% and +4.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates
Select Medical (SEM) delivered earnings and revenue surprises of +14.29% and +1.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Vaxart project agreement change ups funding for oral COVID vaccine candidate
Vaxart project agreement change ups funding for oral COVID vaccine candidate...
Yahoo! Finance: News·9mo ago
News Placeholder
Earnings Preview For Vaxart
read more...
Benzinga·11mo ago
News Placeholder
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching
Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.
Stocktwits·11mo ago
News Placeholder
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside...
Yahoo! Finance: News·1y ago
News Placeholder
Vaxart Stock Is Moving Higher After The Bell: What's Going On?
Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project...
Benzinga·1y ago
News Placeholder
FDA Changes Course, Advises Updated COVID-19 Vaccines Target KP.2 Strain
FDA Changes Course, Advises Updated COVID-19 Vaccines Target KP.2 Strain Authored by Zachary Stieber via The Epoch Times (emphasis ours), A healthcare worker prepares a COVID-19 vaccine...
Zero Hedge·1y ago

Latest VXRT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.